Article Text

Download PDFPDF

Nivolumab-induced polyarthritis
Free
  1. Shoko Kodama1,
  2. Koji Kurose2,
  3. Tomoyuki Mukai1,
  4. Yoshitaka Morita1
  1. 1Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan
  2. 2Department of Respiratory Medicine, Kawasaki Medical School, Kurashiki, Japan
  1. Correspondence to Dr Shoko Kodama, shoko.0513{at}med.kawasaki-m.ac.jp and Dr Yoshitaka Morita, morita{at}med.kawasaki-m.ac.jp

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Description

A 48-year-old Japanese woman with non-small cell lung adenocarcinoma (cT3N2M1b) received nivolumab (an immune checkpoint inhibitor) at a dosage of 3 mg/kg every 2 weeks. Treatment with nivolumab was effective. The primary tumour as well as metastases to the lymph nodes and spine almost completely disappeared, as shown on positron emission tomography-CT before treatment (figure 1A) and 4 months after treatment (figure 1B). However, she developed sustained pain and swelling in the shoulders and knees bilaterally after only one infusion of …

View Full Text